Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24433812.
- Also identified by DOI 10.1016/j.eururo.2013.12.061.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Successful phenotype-genotype correlation is critically dependent on precise definition and reporting of end points in clinical trials. An uniform nomenclature for "deep phenotyping" of metastatic sites in patients with castration-resistant prostate cancer should be mandated in future clinical drug development.
Medical subject headings
- Clinical Trials as Topic
- Prostatic Neoplasms, Castration-Resistant
- Terminology as Topic